Palatin Technologies (PTN) Corporate presentation summary

Technology platform and expertise

• Focus on melanocortin system, specifically MC4R agonists for syndromic and genetic obesity.

• First to gain FDA approval for a melanocortin agent (Vyleesi® for female sexual dysfunction).

• Demonstrated ability to move programs from discovery to FDA approval.

• Strategy leverages deep expertise in melanocortin biology and chemistry.

Leadership and team

• Leadership team with extensive experience in drug development, finance, and business development.

• Key executives have backgrounds at major pharma companies and decades of industry experience.

Development pipeline and programs

• Developing next-generation MC4R selective agonists for rare neuroendocrine diseases: HO, PWS, and BBS.

• Pipeline includes both once-weekly injectable peptides and daily oral small molecules.

• Phase 1 trials for peptides start 1H 2027, with Phase 2/3 in 2H 2027; oral small molecule Phase 1 starts 2H 2027.

• MC4R pathway is validated for obesity management, with significant unmet need in rare diseases.